Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining.

Area of Science:

• Molecular biology
• Cancer research
• Genetics

Background:

• Cancer cells exhibit vulnerabilities to ionizing radiation (IR).
• DNA damage response pathways are crucial for cancer cell survival and treatment response.
• Novel genes influencing radiation response are continually being discovered.

Purpose of the Study:

• To identify novel genetic determinants of cancer cell response to ionizing radiation (IR).
• To functionally characterize the role of ERCC6L2 in DNA damage repair and radiosensitivity.
• To evaluate ERCC6L2 as a potential predictive biomarker for radiotherapy (RT) response.

Main Methods:

• Genome-wide radiogenetic profiling to identify genes affecting IR response.
• Functional assays to assess the role of ERCC6L2 in DNA repair pathways (NHEJ, HR).
• Analysis of ERCC6L2 mutations in human tumors and correlation with patient survival and treatment outcomes.

Main Results:

• ERCC6L2 was identified as a major determinant of IR response, alongside known DNA damage response genes and shieldin/CST complexes.
• ERCC6L2 contributes to non-homologous end joining (NHEJ) and its loss restores DNA end resection and homologous recombination (HR) in BRCA1-deficient cells.
• ERCC6L2 deficiency confers resistance to PARP inhibition in BRCA1/p53-deficient tumors.
• ERCC6L2 mutations in human tumors correlate with improved overall survival in patients treated with RT.

Conclusions:

• ERCC6L2 is a critical regulator of DNA repair and radiosensitivity.
• ERCC6L2 deficiency impacts multiple DNA repair pathways and confers resistance to specific cancer therapies.
• ERCC6L2 mutations serve as a predictive biomarker for radiotherapy response, suggesting its clinical relevance.